New safe­ty da­ta ex­pose po­ten­tial weak­ness as Pfiz­er's abroc­i­tinib takes on Dupix­ent in eczema

Last Sep­tem­ber, when Pfiz­er cel­e­brat­ed pos­i­tive da­ta from a sec­ond Phase III study of abroc­i­tinib, many watch­ers ap­plaud­ed the ef­fi­ca­cy but were still wait­ing to see whether the JAK1 in­hibitor is “safe enough to be a for­mi­da­ble com­peti­tor to Dupix­ent,” the clear leader in the atopic der­mati­tis field. The full slate of safe­ty da­ta are now out and, ac­cord­ing to one an­a­lyst, the an­swer is: prob­a­bly not.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN